Germline BRCA1/2 mutations underlie tumorigenesis in approximately 5–15% of all ovarian cancer (OC), 3% of all breast cancer (BC) and in 10–20% of all triple negative BC cases [1,2,3]. The gene discussed is BRCA1; the disease is ovarian cancer.